TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis


Options:
A: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis


Options:
A: Arm Label: Ixekizumab Q2W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Ixekizumab Q4W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adalimumab Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab Q2W, Ixekizumab Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Q2W
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2
C: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators aimed in this study to investigate the effects of 4 weeks robot-assisted locomotor training on motor recovery of lower extremities and walking ability compared with the conventional gait training in subacute post-stroke non-ambulatory hemiplegic patients.

72 first-ever stroke patients who could not walk independently (FAC \< 2), and suffered within 6 months were enrolled and randomly assigned into 2 groups. The subjects with congestive heart failure, malignancies, cardiopulmonary dysfunctions, and who could not walk independently before stroke attack were excluded.

Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment (NDT) basically. The robotic assisted locomotor training group received additional robotic-assisted gait therapy for 30minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods. The independent walking ability(FAC ≥ 3), Functional Ambulation Category (FAC), Motricity index (MI), Fugl-Meyer assessment (FMA), Modified Barthel Index (MBI), Medical Research Council (MRC) for each lower extremity muscles were assessed before, during (2weeks) and after training. And the independent walking ability were followed until 3 months.


Options:
A: Arm Label: Lokomat Group; Type: EXPERIMENTAL; Interventions: Other: Robot-assisted gait therapy | Arm Label: conventional gait training group; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional gait training | Intervention Type: OTHER; Name: Robot-assisted gait therapy; Assigned to Arm(s): Lokomat Group | Intervention Type: OTHER; Name: conventional gait training; Assigned to Arm(s): conventional gait training group
B: Arm Label: Low-Reward; Type: EXPERIMENTAL; Interventions: Device: Anklebot (Ankle Robot) | Arm Label: High-Reward; Type: ACTIVE_COMPARATOR; Interventions: Device: Anklebot (Ankle Robot) | Intervention Type: DEVICE; Name: Anklebot (Ankle Robot); Assigned to Arm(s): High-Reward, Low-Reward
C: Arm Label: Stride Management Assist (SMA) System; Type: EXPERIMENTAL; Interventions: Device: The Stride Management Assist (SMA) System | Arm Label: Impairment based therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Impairment based therapy | Intervention Type: DEVICE; Name: The Stride Management Assist (SMA) System; Assigned to Arm(s): Stride Management Assist (SMA) System | Intervention Type: OTHER; Name: Impairment based therapy; Assigned to Arm(s): Impairment based therapy
D: Intervention Type: PROCEDURE; Name: Robot-assisted gait training; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Brief Summary: This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.


Options:
A: Arm Label: tiotropium+olodaterol low dose; Type: EXPERIMENTAL; Interventions: Device: Respimat inhaler, Drug: tiotropium+olodaterol (low dose) | Arm Label: tiotropium+olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium + olodaterol (high dose), Device: Respimat inhaler | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Respimat inhaler, Drug: placebo to tiotropium+olodaterol | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium+olodaterol (low dose); Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium + olodaterol (high dose); Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: placebo to tiotropium+olodaterol; Assigned to Arm(s): placebo
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) | Arm Label: Placebo MDI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDI | Arm Label: Spiriva® Respimat® (Tiotropium Bromide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva® Respimat® (Tiotropium Bromide) | Intervention Type: DRUG; Name: GFF MDI (PT003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: Placebo MDI; Assigned to Arm(s): Placebo MDI | Intervention Type: DRUG; Name: Spiriva® Respimat® (Tiotropium Bromide); Assigned to Arm(s): Spiriva® Respimat® (Tiotropium Bromide)
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: QAB149; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAB149 | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: QAB149; Assigned to Arm(s): QAB149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
Brief Summary: The same initial and long-term anticoagulation is suggested for unsuspected pulmonary embolism as for patients with symptomatic embolism. Based on these indications, cancer patients with unsuspected pulmonary embolism would be anticoagulated for at least 6 months or until the disease is active, which in most cases would mean indefinite treatment. In fact, dedicated studies on the treatment of unsuspected pulmonary embolism are missing, leaving doubts over the need for (indefinite) anticoagulation which exposes these patients to an increased risk of major bleeding events. Concerns over the need for anticoagulant treatment may especially hold for pulmonary embolism of the distal pulmonary tree since segmental and sub-segmental PE seem to have a more benign course than more proximal embolism.

The scope of this study is to evaluate the current treatment approaches for unsuspected pulmonary embolism and to assess their efficacy and safety in a large prospective cohort of cancer patients.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
B: Arm Label: Anticoagulants, aspirin; Type: N/A; Interventions: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin | Intervention Type: DRUG; Name: Heparin, fondaparinux, vitamin-K antagonists, aspirin; Assigned to Arm(s): Anticoagulants, aspirin
C: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Robot-Assisted Therapy in Sequential Combination With Constraint-Induced Therapy in Stroke Rehabilitation
Brief Summary: The findings of this project will contribute to the understanding of a comprehensive probe for investigation of the effects of monotherapy versus combination rehabilitation intervention after stroke, including the topics of possible underlying mechanisms of motor recovery as well as the beneficial and adverse effects of intense rehabilitation therapy, prognostic factors of the outcomes, and clinimetric properties of the instruments. The overall findings of this project will be significant in the era of knowledge translation and guide the development of innovative and effective interventions for individualized stroke rehabilitation.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Robot-Assisted Therapy - MIT-MANUS System | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Comparison Therapy | Arm Label: Arm 3; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Robot-Assisted Therapy - MIT-MANUS System; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Intensive Comparison Therapy; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Arm 3
B: Arm Label: RT in sequential combination with dCIT; Type: EXPERIMENTAL; Interventions: Behavioral: RT in sequential combination with dCIT | Arm Label: Distributed Constraint-Induced Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Distributed Constraint-Induced Therapy | Arm Label: Robot-Assisted Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Robot-Assisted Therapy | Arm Label: Dose-matched control therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-matched control therapy | Intervention Type: BEHAVIORAL; Name: RT in sequential combination with dCIT; Assigned to Arm(s): RT in sequential combination with dCIT | Intervention Type: BEHAVIORAL; Name: Distributed Constraint-Induced Therapy; Assigned to Arm(s): Distributed Constraint-Induced Therapy | Intervention Type: BEHAVIORAL; Name: Robot-Assisted Therapy; Assigned to Arm(s): Robot-Assisted Therapy | Intervention Type: BEHAVIORAL; Name: Dose-matched control therapy; Assigned to Arm(s): Dose-matched control therapy
C: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control
D: Intervention Type: DEVICE; Name: robotic device; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Robot-Assisted Therapy in Sequential Combination With Constraint-Induced Therapy in Stroke Rehabilitation
Brief Summary: The findings of this project will contribute to the understanding of a comprehensive probe for investigation of the effects of monotherapy versus combination rehabilitation intervention after stroke, including the topics of possible underlying mechanisms of motor recovery as well as the beneficial and adverse effects of intense rehabilitation therapy, prognostic factors of the outcomes, and clinimetric properties of the instruments. The overall findings of this project will be significant in the era of knowledge translation and guide the development of innovative and effective interventions for individualized stroke rehabilitation.


Options:
A: Arm Label: Low-Reward; Type: EXPERIMENTAL; Interventions: Device: Anklebot (Ankle Robot) | Arm Label: High-Reward; Type: ACTIVE_COMPARATOR; Interventions: Device: Anklebot (Ankle Robot) | Intervention Type: DEVICE; Name: Anklebot (Ankle Robot); Assigned to Arm(s): High-Reward, Low-Reward
B: Arm Label: Stride Management Assist (SMA) System; Type: EXPERIMENTAL; Interventions: Device: The Stride Management Assist (SMA) System | Arm Label: Impairment based therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Impairment based therapy | Intervention Type: DEVICE; Name: The Stride Management Assist (SMA) System; Assigned to Arm(s): Stride Management Assist (SMA) System | Intervention Type: OTHER; Name: Impairment based therapy; Assigned to Arm(s): Impairment based therapy
C: Arm Label: FC-RATE; Type: EXPERIMENTAL; Interventions: Device: Feedback-controlled robotics-assisted treadmill exercise | Arm Label: RATE; Type: ACTIVE_COMPARATOR; Interventions: Device: Robotics-assisted treadmill exercise | Intervention Type: DEVICE; Name: Feedback-controlled robotics-assisted treadmill exercise; Assigned to Arm(s): FC-RATE | Intervention Type: DEVICE; Name: Robotics-assisted treadmill exercise; Assigned to Arm(s): RATE
D: Arm Label: RT in sequential combination with dCIT; Type: EXPERIMENTAL; Interventions: Behavioral: RT in sequential combination with dCIT | Arm Label: Distributed Constraint-Induced Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Distributed Constraint-Induced Therapy | Arm Label: Robot-Assisted Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Robot-Assisted Therapy | Arm Label: Dose-matched control therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-matched control therapy | Intervention Type: BEHAVIORAL; Name: RT in sequential combination with dCIT; Assigned to Arm(s): RT in sequential combination with dCIT | Intervention Type: BEHAVIORAL; Name: Distributed Constraint-Induced Therapy; Assigned to Arm(s): Distributed Constraint-Induced Therapy | Intervention Type: BEHAVIORAL; Name: Robot-Assisted Therapy; Assigned to Arm(s): Robot-Assisted Therapy | Intervention Type: BEHAVIORAL; Name: Dose-matched control therapy; Assigned to Arm(s): Dose-matched control therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
Brief Summary: To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.


Options:
A: Arm Label: Tree Theme Method ® (TTM) intervention; Type: EXPERIMENTAL; Interventions: Other: Tree Theme Method ® (TTM) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Tree Theme Method ® (TTM); Assigned to Arm(s): Tree Theme Method ® (TTM) intervention
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: desvenlafaxine succinate sustained release | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Genetic: Genotyping | Intervention Type: DRUG; Name: desvenlafaxine succinate sustained release; Assigned to Arm(s): 1 | Intervention Type: GENETIC; Name: Genotyping; Assigned to Arm(s): 2
C: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline
D: Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Arm Label: Seroquel XR + ADT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seroquel XR | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole + ADT | Intervention Type: DRUG; Name: Seroquel XR; Assigned to Arm(s): Seroquel XR + ADT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + ADT

Answer: D